COLLABORATION TO DEVELOP EVIDENCE-BASED STRATEGIES TO HELP IMPROVE OSTEOARTHRITIS MANAGEMENT Haleon and University of Sydney launch 5-Year fellowship to research efficacy of dietary supplements
SEGMENT
Filmed in Sydney and online | February 2025
INTERVIEWS
Professor David Hunter,
Florance and Cope Chair of Rheumatology
Co-Director Sydney Musculoskeletal Health Flagship,
University of Sydney
Dr Bincy Thampi,
Medical & Scientific Affairs Lead
Haleon ANZ
Osteoarthritis is a leading cause of disability affecting over 2 million Australians, according to Australian Institute of Health and Welfare report on Chronic musculoskeletal conditions (2024) and 595 million people globally, according to BD 2021 Osteoarthritis Collaborators. Global, regional, and national burden of osteoarthritis, 1990–2020. It represents a significant public health burden that diminishes quality of life among ageing populations.
Consumer healthcare company Haleon is sponsoring a five-year named fellowship program at the University of Sydney that will investigate the therapeutic role of supplements in managing osteoarthritis symptoms and digital health technologies that improve mobility.
The fellowship will fund a postdoctoral researcher to work under the guidance of world leading osteoarthritis expert, rheumatologist and researcher Professor David Hunter.
Australian Health Journal spoke with Professor Hunter who said the research collaboration represents a shared focus and investment in improving osteoarthritis management: “This is a disabling disease that has a huge impact on the people affected.”
“A collaborative effort between researchers and manufacturers will drive innovation and hopefully improve the lives of those impacted by this devastating disease. Use of supplements and natural ingredients in managing osteoarthritis is an exciting area with a lot of potential. I’m not aware of any other long-term, five-year projects of this nature that has osteoarthritis as its focus,” said Hunter.
Haleon and the University of Sydney have a shared goal of finding better management strategies for osteoarthritis and developing better outcomes for the people affected.
Dr Bincy Thampi, Medical & Scientific Affairs Lead at Haleon ANZ, also spoke with Australian Health Journal and says, “Haleon has a strong commitment to scientific research that drives innovative self-care and improves consumer health outcomes.”
“This partnership illustrates Haleon’s commitment to advancing trusted science for our products to better everyday health and we’re excited to see where this partnership with University of Sydney leads,” said Dr Thampi.
-
Misinformation impacts routine vaccines
More significant changes in recent years have been health-related misinformation eroding trust in healthcare professionals, leading to people seeking alternative treatments or avoiding medical advice altogether. This can make it more difficult for healthcare professionals to provide effective treatment and care.
Recent vaccines delivered as part of the COVID-19 response, are having a consequential impact on the uptake of routine vaccines.
Australian Health Journal spoke with Dr Paul Griffin, an Infectious Diseases Physician and Microbiologist at Mater Health, and who has been involved in over 150 clinical trials in the field of infectious disease.
Paul talks about the importance of having reputable sources of information that can used to encourage people to understand what is involved in clinical trials and the roles of vaccines.
-
Career advice from an Emergency Physician in Research
Associate Professor Viet Tran, an experienced emergency physician at the Royal Hobart Hospital. He spoke with Australian Health Journal about the crucial role of emergency departments as the frontline of hospitals, providing immediate care, diagnosis, resuscitation, and serving as a safety net for the healthcare system. Prof. Tran highlights the importance of understanding the daily responsibilities and core aspects of a specialty when choosing a medical career.
-
Cardiologist broadens Tasmania’s surgical abilities
Dr Heath Adams is a Tasmanian born, bred and educated interventional and structural cardiologist who works at Hobart Private and Royal Hobart Hospital and is a researcher through the Menzies Research Institute.
Dr Adams clinical interest and expertise is in the management of aortic stenosis, valvular heart disease and acute coronary syndromes. Dr Adams performs coronary interventions including stenting, and structural heart interventions including TAVI, mitral edge to edge repair, mitral valve replacement and left atrial appendage closure. In 2020, Heath performed the first TAVI in Tasmania, is the clinical lead for the local program at the Royal Hobart Hospital and is a nationally accredited TAVI practitioner.
